Zkusit zdarma
Immuneering Corporation

Immuneering Corporation

IMRX
Cena:
$ 5.39
+0.17 (3.26%)
Valuace
70
Růst
28
Zdraví
78
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

17:00 21-05-2026

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer P...

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

7:35 15-05-2026

- New survival data from Phase 2a clinical trial evaluating atebimetinibmGnP in first-line metastati...

Immuneering Corporation: Updates Inbound At The End Of The Month

Immuneering Corporation: Updates Inbound At The End Of The Month

7:59 12-05-2026

Immuneering Corporation (IMRX) presents promising early data in frontline metastatic pancreatic canc...

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

16:05 21-04-2026

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic canc...

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

9:00 20-04-2026

Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alt...

Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears

Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears

3:02 14-04-2026

Immuneering (NASDAQ: IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session th...

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

16:05 06-04-2026

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage cl...

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Analysts

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Analysts

2:22 23-03-2026

Shares of Immuneering Corporation (NASDAQ: IMRX - Get Free Report) have earned a consensus rating of...

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

16:35 17-03-2026

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients...

Oxford BioMedica (OTCMKTS:OXBDF) and Immuneering (NASDAQ:IMRX) Financial Contrast

Oxford BioMedica (OTCMKTS:OXBDF) and Immuneering (NASDAQ:IMRX) Financial Contrast

2:24 12-03-2026

Oxford BioMedica (OTCMKTS:OXBDF - Get Free Report) and Immuneering (NASDAQ: IMRX - Get Free Report) ...

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

11:15 09-03-2026

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage i...

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

7:45 06-03-2026

- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in fir...

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

16:05 18-02-2026

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage cli...

Immuneering (NASDAQ:IMRX) vs. GRI Bio (NASDAQ:GRI) Head-To-Head Survey

Immuneering (NASDAQ:IMRX) vs. GRI Bio (NASDAQ:GRI) Head-To-Head Survey

1:10 01-02-2026

Immuneering (NASDAQ: IMRX - Get Free Report) and GRI Bio (NASDAQ: GRI - Get Free Report) are both sm...

Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data

Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data

17:45 08-01-2026

Immuneering Corporation remains a Strong Buy after 12-month OS data for atebimetinib + mGnP in 1st-l...

Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower

Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower

9:28 08-01-2026

Immuneering Corporation (NASDAQ: IMRX) stock is trading lower on Thursday after the company shared u...

Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript

Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript

18:47 07-01-2026

Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Tr...

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

16:00 07-01-2026

- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark fro...

Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Rating of “Moderate Buy” from Analysts

Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Rating of “Moderate Buy” from Analysts

1:30 07-01-2026

Immuneering Corporation (NASDAQ: IMRX - Get Free Report) has been assigned an average rating of "Mod...

All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy

All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy

13:01 29-12-2025

Immuneering (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the...

close

IMMUNEERING ANNOUNCES EXCEPTIONAL 64% OVERALL SURVIVAL AT 12 MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP

07-01-2026
- REPORTED 12-MONTH OVERALL SURVIVAL (OS) IN PHASE 2A CLINICAL TRIAL NEARLY DOUBLE THE BENCHMARK FRO...
Více zde

IMMUNEERING TO ANNOUNCE 12-MONTH OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON JANUARY 7, 2026

23-12-2025
IMMUNEERING TO ANNOUNCE 12-MONTH OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB ...
Více zde

IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINIB TRIAL FOR FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS, SECURING ALIGNMENT WITH FDA AND EMA

17-12-2025
– END-OF-PHASE 2 INTERACTIONS WITH FDA COMPLETE; SCIENTIFIC ADVICE RECEIVED FROM EMA – – COMPA...
Více zde

IMMUNEERING TO BE ADDED TO THE NASDAQ BIOTECHNOLOGY INDEX (NBI)

16-12-2025
NEW YORK, DEC. 16, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A LATE-STAGE CLI...
Více zde

IMMUNEERING TO PRESENT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

25-11-2025
NEW YORK, NOV. 25, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAGE...
Více zde

IMMUNEERING REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS AND CLINICAL UPDATES

12-11-2025
- ANNOUNCED EXTRAORDINARY 86% OVERALL SURVIVAL AT 9 MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS ...
Více zde

IMMUNEERING TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE NEW CLINICAL CASE STUDIES, ON WEDNESDAY, NOVEMBER 12, 2025

04-11-2025
- NEW CASE STUDIES ON FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB IN COMBINATION...
Více zde

IMMUNEERING TO DISCUSS RECENTLY ANNOUNCED OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON MONDAY, SEPTEMBER 29, 2025

26-09-2025
NEW YORK, SEPT. 26, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAG...
Více zde

IMMUNEERING ANNOUNCES PRICING OF $175 MILLION UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK AND CONCURRENT $25 MILLION PRIVATE PLACEMENT OF CLASS A COMMON STOCK TO SANOFI

25-09-2025
IMMUNEERING ANNOUNCES PRICING OF $175 MILLION UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK A...
Více zde

IMMUNEERING ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK AND PRE-FUNDED WARRANTS AND PROPOSED CONCURRENT PRIVATE PLACEMENT OF CLASS A COMMON STOCK AND CLASS B COMMON STOCK TO SANOFI

24-09-2025
IMMUNEERING ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF CLASS A COMMON STOCK AND PRE-FUNDED W...
Více zde

IMMUNEERING ANNOUNCES EXTRAORDINARY 86% OVERALL SURVIVAL AT 9 MONTHS IN FIRST-LINE PANCREATIC CANCER PATIENTS TREATED WITH ATEBIMETINIB + MGNP

24-09-2025
- 86% OVERALL SURVIVAL (OS) OBSERVED AT 9 MONTHS; STANDARD OF CARE BENCHMARK IS ~47% - - 53% PROGRES...
Více zde

IMMUNEERING APPOINTS DR. THOMAS SCHALL AS CHAIRMAN OF THE BOARD

16-09-2025
NEW YORK, SEPT. 16, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICAL-STAG...
Více zde

IMMUNEERING TO ANNOUNCE UPDATED OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON SEPTEMBER 25

10-09-2025
IMMUNEERING TO ANNOUNCE UPDATED OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB +...
Více zde

IMMUNEERING ANNOUNCES CLOSING OF $25 MILLION PRIVATE PLACEMENT

26-08-2025
CAMBRIDGE, MASS., AUG. 26, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINIC...
Více zde

IMMUNEERING ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH LILLY TO EVALUATE ATEBIMETINIB IN COMBINATION WITH OLOMORASIB

25-08-2025
- IMMUNEERING TO EVALUATE ATEBIMETINIB IN COMBINATION WITH OLOMORASIB IN PLANNED PHASE 2 TRIAL IN PA...
Více zde

IMMUNEERING ANNOUNCES $25 MILLION PRIVATE PLACEMENT

21-08-2025
CAMBRIDGE, MASS., AUG. 21, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINIC...
Více zde

IMMUNEERING REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

13-08-2025
- COMPANY NOW PLANS TO SHARE UPDATED OS AND PFS DATA FROM FIRST-LINE PANCREATIC CANCER PATIENTS (N =...
Více zde

IMMUNEERING GRANTED U.S. COMPOSITION OF MATTER PATENT FOR HIGHLY DIFFERENTIATED CANCER DRUG CANDIDATE ATEBIMETINIB

09-07-2025
- NEWLY ISSUED U.S. COMPOSITION OF MATTER PATENT EXPECTED TO PROVIDE EXCLUSIVITY INTO 2042, WITH SUB...
Více zde

IMMUNEERING REPORTS POSITIVE OVERALL SURVIVAL DATA FOR ATEBIMETINIB (IMM-1-104) FROM ONGOING PHASE 2A TRIAL IN FIRST-LINE PANCREATIC CANCER PATIENTS

17-06-2025
- 94% OS AND 72% PFS OBSERVED AT 6 MONTHS FOR ATEBIMETINIB (IMM-1-104) IN COMBINATION WITH MODIFIED ...
Více zde

IMMUNEERING TO PROVIDE UPDATES FROM PHASE 2A CLINICAL TRIAL OF IMM-1-104 IN FIRST-LINE PANCREATIC CANCER PATIENTS ON TUESDAY, JUNE 17, 2025

16-06-2025
CAMBRIDGE, MASS., JUNE 16, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINIC...
Více zde

IMMUNEERING TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

29-05-2025
CAMBRIDGE, MASS., MAY 29, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINICA...
Více zde

IMMUNEERING REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

05-05-2025
- PROGRESSION-FREE SURVIVAL DATA FROM MORE THAN 30 PATIENTS WITH FIRST LINE PANCREATIC CANCER IN THE...
Více zde

IMMUNEERING TO PRESENT AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

02-04-2025
CAMBRIDGE, MASS., APRIL 02, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINI...
Více zde

IMMUNEERING CORPORATION ANNOUNCES GRANT OF INDUCEMENT AWARD

21-03-2025
CAMBRIDGE, MASS., MARCH 21, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINI...
Více zde

IMMUNEERING REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

20-03-2025
- REPORTED POSITIVE DATA UPDATES FROM ITS ONGOING PHASE 2A TRIAL OF LEAD PROGRAM IMM-1-104, INCLUDIN...
Více zde

IMMUNEERING NAMES DR. IGOR MATUSHANSKY AS CHIEF MEDICAL OFFICER

20-03-2025
INDUSTRY VETERAN BRINGS EXTENSIVE ONCOLOGY DRUG DEVELOPMENT EXPERTISE AND EXPERIENCE IN CLINICAL TRE...
Více zde

IMMUNEERING TO PRESENT AT THE OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE

03-02-2025
CAMBRIDGE, MASS., FEB. 03, 2025 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINIC...
Více zde

IMMUNEERING LAUNCHES PANCREATIC CANCER ADVISORY BOARD

19-12-2024
- ESTABLISHMENT REFLECTS THE CLINICAL PROGRESS OF IMM-1-104 AND ITS PROMISE IN PANCREATIC CANCER - -...
Více zde

IMMUNEERING GRANTED FDA FAST TRACK DESIGNATION FOR IMM-1-104 IN ADVANCED MELANOMA

12-12-2024
- IMM-1-104 HAS THE POTENTIAL TO BENEFIT MELANOMA PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT ...
Více zde

IMMUNEERING TO PRESENT AT THE PIPER SANDLER 36ᵗʰ ANNUAL HEALTHCARE CONFERENCE

27-11-2024
CAMBRIDGE, MASS., NOV. 27, 2024 (GLOBE NEWSWIRE) -- IMMUNEERING CORPORATION (NASDAQ: IMRX), A CLINIC...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-07 00:00:008-KStáhnout
2025-11-12 00:00:008-KStáhnout
2025-11-12 00:00:0010-QStáhnout
2025-09-25 01:00:008-KStáhnout
2025-09-25 00:00:008-KStáhnout
2025-09-24 01:00:008-KStáhnout
2025-09-24 00:00:008-KStáhnout
2025-08-25 01:00:008-KStáhnout
2025-08-25 00:00:008-KStáhnout
2025-08-13 01:00:008-KStáhnout
2025-08-13 01:00:0010-QStáhnout
2025-08-13 00:00:008-KStáhnout
2025-08-13 00:00:0010-QStáhnout
2025-06-17 01:00:008-KStáhnout
2025-06-17 00:00:008-KStáhnout
2025-06-16 01:00:008-KStáhnout
2025-06-16 00:00:008-KStáhnout
2025-05-05 01:00:008-KStáhnout
2025-05-05 01:00:0010-QStáhnout
2025-05-05 00:00:008-KStáhnout
2025-05-05 00:00:0010-QStáhnout
2025-03-20 00:00:008-KStáhnout
2025-03-20 00:00:0010-KStáhnout
2025-03-19 23:00:008-KStáhnout
2025-03-19 23:00:0010-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2025-01-07 00:00:008-KStáhnout
2025-01-06 23:00:008-KStáhnout
2024-11-13 00:00:008-KStáhnout
2024-11-13 00:00:0010-QStáhnout
2024-11-12 23:00:008-KStáhnout
2024-11-12 23:00:0010-QStáhnout
2024-09-12 01:00:008-KStáhnout
2024-09-12 00:00:008-KStáhnout
2024-08-06 01:00:008-KStáhnout
2024-08-06 01:00:0010-QStáhnout
2024-08-06 00:00:008-KStáhnout
2024-08-06 00:00:0010-QStáhnout
2024-06-13 01:00:008-KStáhnout
2024-06-13 00:00:008-KStáhnout
2024-05-23 01:00:008-KStáhnout
2024-05-23 00:00:008-KStáhnout
2024-05-07 01:00:008-KStáhnout
2024-05-07 01:00:0010-QStáhnout
2024-05-07 00:00:008-KStáhnout
2024-05-07 00:00:0010-QStáhnout
2024-03-14 00:00:008-KStáhnout
2024-03-13 23:00:008-KStáhnout
2024-03-01 00:00:008-KStáhnout
2024-03-01 00:00:0010-KStáhnout
2024-02-29 23:00:008-KStáhnout
2024-02-29 23:00:0010-KStáhnout
2024-02-02 00:00:008-KStáhnout
2024-02-01 23:00:008-KStáhnout
2023-11-09 00:00:008-KStáhnout
2023-11-09 00:00:0010-QStáhnout
2023-11-08 23:00:008-KStáhnout
2023-11-08 23:00:0010-QStáhnout
2023-08-03 01:00:008-KStáhnout
2023-08-03 01:00:0010-QStáhnout
2023-08-03 00:00:008-KStáhnout
2023-08-03 00:00:0010-QStáhnout
2023-06-15 01:00:008-KStáhnout
2023-06-15 00:00:008-KStáhnout
2023-06-14 01:00:008-KStáhnout
2023-06-14 00:00:008-KStáhnout
2023-05-04 01:00:008-KStáhnout
2023-05-04 01:00:0010-QStáhnout
2023-05-04 00:00:008-KStáhnout
2023-05-04 00:00:0010-QStáhnout
2023-04-19 01:00:008-KStáhnout
2023-04-19 00:00:008-KStáhnout
2023-04-18 01:00:008-KStáhnout
2023-04-18 00:00:008-KStáhnout
2023-03-06 00:00:008-KStáhnout
2023-03-06 00:00:0010-KStáhnout
2023-03-05 23:00:008-KStáhnout
2023-03-05 23:00:0010-KStáhnout
2022-11-10 00:00:008-KStáhnout
2022-11-10 00:00:0010-QStáhnout
2022-11-09 23:00:008-KStáhnout
2022-11-09 23:00:0010-QStáhnout
2022-08-10 01:00:008-KStáhnout
2022-08-10 01:00:0010-QStáhnout
2022-08-10 00:00:008-KStáhnout
2022-08-10 00:00:0010-QStáhnout
2022-07-25 01:00:008-KStáhnout
2022-07-25 00:00:008-KStáhnout
2022-06-24 01:00:008-KStáhnout
2022-06-24 00:00:008-KStáhnout
2022-05-10 01:00:008-KStáhnout
2022-05-10 01:00:0010-QStáhnout
2022-05-10 00:00:008-KStáhnout
2022-05-10 00:00:0010-QStáhnout
2022-03-10 00:00:008-KStáhnout
2022-03-10 00:00:0010-KStáhnout
2022-03-09 23:00:008-KStáhnout
2022-03-09 23:00:0010-KStáhnout
2022-01-18 00:00:008-KStáhnout
2022-01-17 23:00:008-KStáhnout
2021-12-22 00:00:008-KStáhnout
2021-12-21 23:00:008-KStáhnout
2021-11-09 00:00:008-KStáhnout
2021-11-09 00:00:0010-QStáhnout
2021-11-08 23:00:008-KStáhnout
2021-11-08 23:00:0010-QStáhnout
2021-09-09 01:00:008-KStáhnout
2021-09-09 01:00:0010-QStáhnout
2021-09-09 00:00:008-KStáhnout
2021-09-09 00:00:0010-QStáhnout
preloader